The Challenge
After seven years of treatment—including prostatectomy, pelvic and bone radiation, continuous androgen deprivation therapy, and second-generation hormone drugs—Reynolds' PSA continued to rise and new, painful bone metastases appeared.
Our Impact
Cancer Commons recommended mutational testing via liquid biopsy, which revealed a very high tumor mutational burden—an uncommon but actionable finding in prostate cancer and a strong indicator of likely benefit from immune checkpoint therapy.
The Outcome
The patient began treatment with Keytruda, experienced a rapid PSA drop and complete resolution of bone lesions, and remains disease-free four years later.
